Lpath Inc (LPTN)

1.92
0.18 8.57
NASDAQ : Health Care
Prev Close 2.10
Open 2.05
Day Low/High 1.81 / 2.05
52 Wk Low/High 1.68 / 5.88
Volume 89.58K
Avg Volume 248.30K
Exchange NASDAQ
Shares Outstanding 2.36M
Market Cap 4.52M
EPS -5.50
P/E Ratio 0.35
Div & Yield N.A. (N.A)

Latest News

Lpath Completes Dosing In The Lpathomab Phase 1 Safety Study

Lpath Completes Dosing In The Lpathomab Phase 1 Safety Study

Lpathomab is well-tolerated at all doses tested in healthy volunteers

Lpath To Hold Corporate Update Conference Call And Live Webcast On Tuesday, November 17th

Lpath To Hold Corporate Update Conference Call And Live Webcast On Tuesday, November 17th

Company to Present Additional Data From the Nexus Phase 2 Study of iSONEP™

Lpath Announces Plan To Begin Lpathomab Clinical Trial

Lpath Announces Plan To Begin Lpathomab Clinical Trial

Company Provides Update on Strategic Priorities

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels. Here's how to trade them.

4 Big-Volume Stocks Triggering Breakout Trades

4 Big-Volume Stocks Triggering Breakout Trades

These stocks rising on unusual volume are within range of triggering breakout trades.

Lpath Reports Results For ISONEP™ In Patients With Wet Age-related Macular Degeneration

Lpath Reports Results For ISONEP™ In Patients With Wet Age-related Macular Degeneration

Study Did Not Meet Primary or Key Secondary Endpoints

Lpath Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma

Lpath Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma

Conference Call Scheduled for Today at 4:30 p.m. ET to Provide Investor Update

Lpath Completes Enrollment In Its Phase 2 Clinical Trial Of ISONEP For Wet Age-Related Macular Degeneration

Lpath Completes Enrollment In Its Phase 2 Clinical Trial Of ISONEP For Wet Age-Related Macular Degeneration

Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update

Lpath Announces Departure Of CEO

Lpath Announces Departure Of CEO

Scott Pancoast Resigns as President & CEO; Board Appoints Michael Lack as Interim CEO

Lpath Granted Key European Patent Related To ISONEP And ASONEP Programs

Lpath Granted Key European Patent Related To ISONEP And ASONEP Programs

Patent Provides Coverage for Lpath's Anti-S1P Antibody in Europe

Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

Based on encouraging progression-free survival data, Lpath extends the study to a second cohort and considers additional proof-of-concept studies

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the Health Care sector lower today.

Lpath Lands Fast-Track SBIR Grant From The NIH For Traumatic Brain Injury Treatment

Lpath Lands Fast-Track SBIR Grant From The NIH For Traumatic Brain Injury Treatment

SBIR Grant from the National Institutes of Neurological Diseases and Stroke Provides Funds for IND-enabling Studies of Lpathomab

Lpath And Walter Reed Army Institute For Research Begin Efficacy Study Using Lpathomab In Traumatic Brain Injury Models

Lpath And Walter Reed Army Institute For Research Begin Efficacy Study Using Lpathomab In Traumatic Brain Injury Models

The Department of Defense's WRAIR will study Lpath's anti-LPA antibody in the blast injury model of TBI

3 Stocks Under $10 to Watch

3 Stocks Under $10 to Watch

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

New Published Paper Shows Efficacy Of Lpath's Anti-LPA Antibody, Lpathomab, In Traumatic Brain Injury Models

New Published Paper Shows Efficacy Of Lpath's Anti-LPA Antibody, Lpathomab, In Traumatic Brain Injury Models

Publication Further Validates Lpath's Approach to Targeting Bioactive Lipids for Drug Discovery